CABA Stock On Track For Best Day In 6 Months After Positive Early Results From Cell Therapy Trial

• The company was studying its therapy called rese-cel at the lowest dose without preconditioning in patients with pemphigus vulgaris.
• After discontinuing all immunomodulators, two of the four patients demonstrated compelling clinical activity through 6 months of follow-up.
• While a mild immune reaction was observed in one of the patients, no neurological complications were observed, the company said.

Shares of Cabaletta Bio Inc (CABA) jumped 30% on Monday, on track for its best day since October, after the company reported promising early data from four patients with an autoimmune disease treated with the company’s experimental cell therapy, demonstrating clinical activity without any preconditioning chemotherapy.

The company said that four patients with pemphigus vulgaris, an autoimmune disease causing severe blistering of the skin, received its therapy called rese-cel at the lowest dose without preconditioning with cyclophosphamide and fludarabine. After discontinuing all immunomodulators, two of the four patients demonstrated compelling clinical activity through 6 months of follow-up, while three patients remained off all immunomodulators and steroids, the company said.  

While a mild immune reaction was observed in one of the patients, no neurological complications were observed, the company said.  The company also said that it has enrolled patients to test a higher dose of its therapy based on the safety profile observed in the lower dose cohort.

Data from the higher dose population is now expected in the second half of 2026.

CABA’s $150M Financing

Separately, Cabaletta Bio priced an underwritten offering of 51.73 million shares of common stock at $2.90 per share, expected to generate gross proceeds of approximately $150 million before underwriting discounts, commissions, and expenses.  

The financing drew participation from big-pharma company Eli Lilly and Company, in addition to existing investors including Bain Capital Life Sciences, Adage Capital Management, and Cormorant Asset Management.

How Did CABA Retail Traders React?

On Stocktwits, retail sentiment around CABA stock rose from 'neutral' to 'bullish' territory over the past 24 hours, while message volume increased from 'normal' to 'high' levels.

A Stocktwits user opined that the company's shares are cheap at current prices.

Another voiced optimism about Eli Lilly’s participation in the financing round, opining that it could lead to a “full collaboration or acquisition later.”

A third user opined that there is potential for making “mega money” on the stock.

CABA stock has gained 200% over the past 12 months.

Read More: Circle Stock Extends Gains, Hits 1-Month High On CLARITY Act Momentum

For updates and corrections, email newsroom[at]stocktwits[dot]com.